anti-doping testing is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
== Further reading == Kielley WW, Bradley LB (1954). "Glutathione thiolesterase". J. Biol. Chem. 206 (1): 327–33. doi:10.1016/S0021-9258(18)71321-5. PMID 13130552. Murata, Kousaku; Sato, Nobuyuki; Rhee, Hae-ik; Watanabe, Kunihiko; Kimura, Akira (1987). "Purification and Characterization of Glutathione Thiol Esterase from Saccharomyces cerevisiae". Agricultural and Biological Chemistry. 51 (7): 1901–1907. doi:10.1080/00021369.1987.10868321. Uotila, Lasse (1979). "Glutathione thiol esterases of human red blood cells". Biochimica et Biophysica Acta (BBA) - Protein Structure. 580 (2): 277–288. doi:10.1016/0005-2795(79)90140-5. PMID 93000.
Moxidectin has a longer half-life than ivermectin and may eventually supplant ivermectin as it is a more potent microfilaricide, but there is a need for additional clinical trials, with long-term follow-up, to assess whether moxidectin is safe and effective for treatment of nematode infection in children and women of childbearing potential. There is tentative evidence that ivermectin kills bedbugs, as part of integrated pest management for bedbug infestations. However, such use may require a prolonged course of treatment which is of unclear safety.
The presence of radiologically opaque breast implants (either saline or silicone) might interfere with the radiographic sensitivity of the mammograph, that is, the image might not show any tumor(s) present. In this case, an Eklund view mammogram is required to ascertain either the presence or the absence of a cancerous tumor, wherein the breast implant is manually displaced against the chest wall and the breast is pulled forward, so that the mammograph can visualize a greater volume of the internal tissues; nonetheless, approximately one-third of the breast tissue remains inadequately visualized, resulting in an increased incidence of mammograms with false-negative results. The breast cancer studies Cancer in the Augmented Breast: Diagnosis and Prognosis (1993) and Breast Cancer after Augmentation Mammoplasty (2001) of women with breast implant prostheses reported no significant differences in disease-stage at the time of the diagnosis of cancer; prognoses are similar in both groups of women, with augmented patients at a lower risk for subsequent cancer recurrence or death. Conversely, the use of implants for breast reconstruction after breast cancer mastectomy appears to have no negative effect upon the incidence of cancer-related death. That patients with breast implants are more often diagnosed with palpable—but not larger—tumors indicates that equal-sized tumors might be more readily palpated in augmented patients, which might compensate for the impaired mammogram images.
The light source shines onto or through the sample. The sample transmits or reflects light. The detector detects how much light was reflected from or transmitted through the sample. The detector then converts how much light the sample transmitted or reflected into a number.
Sources: en.wikipedia.org
Analysis of an intermediate plasminogen structure suggests that plasminogen conformational change to the open form is initiated through KR-5 transiently peeling away from the PAp domain. These movements expose the KR5 lysine-binding site to potential binding partners, and suggest a requirement for spatially distinct lysine residues in eliciting plasminogen recruitment and conformational change respectively.
Analytical chemistry has applications across science and industry. It is fundamental to forensic science (e.g., DNA fingerprinting and toxicology), bioanalysis (e.g., measuring drug concentrations in pharmacokinetic studies), clinical analysis (e.g., blood glucose monitoring and COVID-19 PCR testing), environmental monitoring (e.g., testing for pollutants in water and air), and materials science (e.g., quality control of semiconductors and nanomaterials). Great effort is being put into shrinking the analysis techniques to chip size. Although few examples of such systems compete with traditional analysis techniques, potential advantages include size/portability, speed, and cost. Micro total analysis system (μTAS) or lab-on-a-chip. Microscale chemistry reduces the amount of chemicals used. Many developments improve the analysis of biological systems. Examples of rapidly expanding fields in this area are genomics, DNA sequencing and related research in genetic fingerprinting and DNA microarray; proteomics, the analysis of protein concentrations and modifications, especially in response to various stressors, at various developmental stages, or in various parts of the body; metabolomics, which deals with metabolites; transcriptomics, including mRNA and associated fields; lipidomics, dealing with lipids and its related fields; peptidomics, dealing with peptides and its related fields; and metallomics, dealing with metal concentrations and especially with their binding to proteins and other molecules.
Despite requiring a deviation from room temperature of less than half that seen in hot branding, taking the branding iron to its cryogenic working temperature is a far more involved and time-consuming process than that used in hot-iron branding. Specialized irons are required as well as an insulating container in which to chill them. Cryogenic material such as dry ice or liquid nitrogen is also essential. These may be difficult to procure, transport and store in remote areas (although liquid nitrogen is frequently on hand at large ranching operations to preserve banked semen.) Further, a freeze brand normally reaches its greatest legibility only after several months because white hair must first grow back. Immediately visible freeze brands can be produced by longer branding times, though these also cause the permanent loss of hair. Successful freeze brands must also be preceded by careful shaving of the animal's coat to expose its skin. Finally, there remain fourteen American states do not recognize freeze branding as a legal means of indicating livestock ownership.
On February 11, 2015, Newsom announced that he was opening a campaign account for governor in the 2018 elections, allowing him to raise funds for a campaign to succeed Brown as governor of California. On June 5, 2018, he finished in the top two in the nonpartisan blanket primary, and he defeated Republican John H. Cox by a landslide in the November 6 general election.
The rate of proteolysis may also depend on the physiological state of the organism, such as its hormonal state as well as nutritional status. In time of starvation, the rate of protein degradation increases.
Sources: en.wikipedia.org
== History == Xylazine was discovered as an antihypertensive agent in 1962 by Farbenfabriken Bayer in Leverkusen, West Germany. In human trials xylazine was found to depress the central nervous system leading to the discontinuation of further research for its use in humans and it was instead marketed as a veterinary sedative, starting in the late 1960s. Xylazine proved popular and in the 1970s became one of the most common large animal sedatives. Xylazine's muscle relaxant effect inhibits the transmission of neural impulses in the central nervous system. In 1981 a study discovered that the cause sedation was due to xylazine's effect on the α2-adrenergic receptor. This led to the development of other α2-adrenergic receptor agonists such as detomidine, medetomidine, dexmedetomidine, and romifidine. In the United States, xylazine was approved by the FDA only for veterinary use as a sedative, analgesic, and muscle relaxant in dogs, cats, horses, elk, fallow deer, mule deer, sika deer, and white-tailed deer. In scientific research using animal experiments, xylazine is a component of the most common anesthetic, ketamine-xylazine (see: Rodent cocktail), to anesthetize rats, mice, hamsters, and guinea pigs. Xylazine has not previously been a controlled substance; however, due to illicit abuse, legislative restrictions have been proposed in multiple countries. Xylazine was made a class C drug in the UK on 15 January 2025.
For services to People with Dementia and their Families. Dr. Emma Lucy Wilson. Director of Technical, Production and Costume, Royal Opera House. For services to the Performing Arts. William Wilson. Senior Officer, National Crime Agency. For services to Law Enforcement. Belinda Ann Winstone. Team Leader, Army Bereavement and Aftercare Services. For services to Military Families. Joan Harris Winterkorn. Archive and Manuscript Consultant and Member, Acceptance in Lieu Panel, Arts Council England. For services to Heritage and Culture. Theresa Wise. Chief Executive, Royal Television Society. For services to Broadcasting. Nicola Clare Wood. Senior Independent Director, Information Commissioner's Office. For services to Regulation. Mary Elizabeth Woods. Lately Nurse Consultant, The Royal Marsden NHS Foundation Trust. For services to Lymphoedema. Caroline Valerie Wright. Early Childhood Director, Bright Horizons Nursery. For services to Early Years Education. Judith Kathleen Wright. Trustee, Orders of St John Care Trust and lately Chair, St John Priory Group for Buckinghamshire. For voluntary service to the Order of St John. Stephen Richard Wright. Broadcaster. For services to Radio. Gloria Ingrid Wyse. Head of Research and Content, Business in the Community. For services to Diversity and Inclusion. Dr. Richard Kenneth Howard Wyse. Director of Clinical Development, Cure Parkinson's. For services to Medicine in Parkinson's Disease. Susan Yates. Officer, National Crime Agency. For services to Law Enforcement. Allan Reid Young. Head of Instrumental Music, Perth and Kinross.
== Related compounds == Cyclohexanehexone can be viewed as the neutral counterpart of the rhodizonate anion C6O2−6. The singly charged anion C6O−6 has been detected in mass spectrometry experiments, formed by oligomerization of carbon monoxide through the formation of molybdenum carbonyls. According to X-ray diffraction analysis, the reagent traded under the name "cyclohexanehexone octahydrate" or equivalent names is actually dodecahydroxycyclohexane dihydrate—the geminal diol derivative of the six ketone groups with an additional two molecules of water—a solid that decomposes at 95 °C. In 1966, Howard E. Worne of Natick Chemical Industries patented compounds with formulas C10O8 and C14O10, which can be described as the fusion of two or three molecules of C6O6, claimed to be produced by the action of ultraviolet radiation on a hot water solution of the parent compound.
, the first step is to linearise around the disease-free equilibrium (DFE), but for the infected subsystem of non-linear ODEs which describe the production of new infections and changes in state among infected individuals. Epidemiologically, the linearisation reflects that
Cox Plate (2009, 2010), Tattersalls Gold Cup (2011, 2012), Prince of Wales's Stakes (2012) (foaled 2006). (death announced on this date) 23 October – Piera McArthur, painter (born 1929). 27 October – Robert Neale, literary scholar and university orator (Massey University) (born 1933). 29 October – Mick Bremner, rugby union player (Auckland, Canterbury, national team) (born 1930). 30 October – Alan Vest, association football player (Perth Azzurri, national team) and manager (Sarawak FA, Perth Glory) (born 1939). 31 October Chris Barfoot, realtor (Barfoot & Thompson), conservationist (Tahuna Torea Nature Reserve), and pacifist, secretary of Anglican Pacifist Fellowship New Zealand (1962–1968, 1992–2016) (born 1930). Tim Finn, viticulturist (Neudorf Vineyards) (born 1946).
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.